title: Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
abstract: Additional chromosome abnormalities (ACAs) occur in less than 10% of cases at diagnosis of Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). In some cases, on the basis of the persistence of the ACAs in Ph-negative cells after response to imatinib, a secondary origin of the Ph chromosome has been demonstrated. In this study, the possible prognostic value of this phenomenon was evaluated. Thirty-six Ph-positive CML patients were included in the study. In six patients, ACAs persisted after the disappearance of the Ph. A complete cytogenetic response (CCR) was obtained in five of these six patients, and five of six also had a high Sokal score. In all the other cases, ACAs disappeared together (in cases of response to therapy with imatinib) or persisted with the Ph (in cases of no response to imatinib). In the former cases, the primary origin of the Ph was demonstrated. CCR was obtained in 22 cases (17 with low to intermediate Sokal scores), while no response was observed in 8 patients (5 with a high Sokal score). Sokal score seems to maintain its prognostic value for patients in whom the Ph occurs as a primary event, but not in those in whom it occurs as a secondary one.
authors.affiliation: Oncology-Hematology Department, "S. Maria delle Croci" Hospital, viale Randi, 5, 48121 Ravenna, Italy. a.zaccaria@ausl.ra.it
authors.forename: Alfonso
authors.initials: A
authors.lastname: Zaccaria
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Testoni
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Valenti
authors.forename: Simona
authors.initials: S
authors.lastname: Luatti
authors.forename: Michela
authors.initials: M
authors.lastname: Tonelli
authors.forename: Giulia
authors.initials: G
authors.lastname: Marzocchi
authors.forename: Raffaella
authors.initials: R
authors.lastname: Cipriani
authors.forename: Carmen
authors.initials: C
authors.lastname: Baldazzi
authors.forename: Barbara
authors.initials: B
authors.lastname: Giannini
authors.forename: Monica
authors.initials: M
authors.lastname: Stacchini
authors.forename: Carla
authors.initials: C
authors.lastname: Gamberini
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Annalisa
authors.initials: A
authors.lastname: Azzena
authors.forename: Francesco
authors.initials: F
authors.lastname: Cavazzini
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Cianciulli
authors.forename: Alessia
authors.initials: A
authors.lastname: Dalsass
authors.forename: Emilio
authors.initials: E
authors.lastname: Donti
authors.forename: Emilia
authors.initials: E
authors.lastname: Giugliano
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Maria Grazia
authors.initials: MG
authors.lastname: Grimoldi
authors.forename: Sonia
authors.initials: S
authors.lastname: Ronconi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Santoro
authors.forename: Francesco
authors.initials: F
authors.lastname: Spedicato
authors.forename: Lucia
authors.initials: L
authors.lastname: Zanatta
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002869:Chromosome Aberrations; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases